Study inclusion consisted of meta-analyses of randomized controlled trials (RCTs), with subjects aged 18 years or older, using L-carnitine as the intervention, with a control or placebo group, a duration of follow-up of 2 weeks, and outcomes including lipid profiles and changes in TG, HDL-C, LDL-C, and TC
Your clinician will consider factors including: Your overall health status and comorbidities The degree of obesity and associated health risks Previous history of biliary symptoms The urgency of weight loss for other medical conditions In some cases, particularly where obesity poses immediate health risks (such as severe type 2 diabetes or cardiovascular disease), the benefits of weight loss may outweigh the potential gallstone risks
Several of these trials are part of Cure Parkinsons and Van Andel Institutes International Linked Clinical Trials program, which investigates whether medications developed for other diseases may also have applicability in Parkinsons
Hallmarks of neurodegenerative diseases